4//SEC Filing
Dolan Daniel 4
Accession 0001104659-22-010489
CIK 0001641640other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 6:39 PM ET
Size
9.1 KB
Accession
0001104659-22-010489
Insider Transaction Report
Form 4
Dolan Dan
Chief Financial Officer
Transactions
- Award
Share Options
2022-01-28+83,200→ 83,200 totalExercise: $0.45Exp: 2032-01-27→ Ordinary Shares (83,200 underlying) - Award
Restricted Stock Units
2022-01-28+41,600→ 41,600 total→ Ordinary Shares (41,600 underlying)
Footnotes (4)
- [F1]The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
- [F2]Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
- [F3]The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date.
- [F4]Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.
Documents
Issuer
Nabriva Therapeutics plc
CIK 0001641640
Entity typeother
Related Parties
1- filerCIK 0001826818
Filing Metadata
- Form type
- 4
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 6:39 PM ET
- Size
- 9.1 KB